<DOC>
	<DOCNO>NCT02422290</DOCNO>
	<brief_summary>This pilot study propose determine acceptability , feasibility potential efficacy ketamine , medication modulates glutamate brain , rapid treatment obsessive-compulsive disorder ( OCD ) symptoms adolescent young adult OCD . This study recruit 5 youth ( age 14-20 ) diagnose clinically significant OCD fail least two adequate trial Serotonin Reuptake Inhibitor ( SRI ) medication course Cognitive-Behavioral Therapy ( CBT ) OCD past . Participants receive single infusion intravenous ketamine assess regular interval post-infusion 14 day . At end 14-day treatment phase , participant offer three month open treatment OCD medication and/or CBT .</brief_summary>
	<brief_title>Ketamine Treatment Pediatric-Refractory Obsessive-Compulsive Disorder ( OCD )</brief_title>
	<detailed_description>See Brief Summary description .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1 . Participant must 1420 year age time consent ( postpubertal ) 2 . Participant parent/guardian must able read understand English 3 . Participant must physically healthy weigh least 25kg . If female , must pregnant . 4 . Participant must fulfill DSMV criterion OCD , OCD principal disorder ( i.e. , currently severe need treatment ) OCD least six month . 5 . Participant must score ≥ 16 Children 's YaleBrown Obsessive Compulsive Scale ( CYBOCS ) prior enter study , report least moderate severity obsession and/or compulsions.. 6 . Participant must try fail least two adequate trial SRI medication course CBT unless participant unable tolerate CBT treatment . In order meet criterion least two adequate trial SRI medication , participant must stable minimal adequate dose least two SRI medication define literature least 12 week , document history intolerable adverse effect higher dose evaluate study psychiatrist therefore unable increase dose complete full 12 week , refuse SRI trial . Congruent literature , range minimally adequate dos treat OCD follow : Clomipramine ( Anafranil ) 75100 mg/day ; Fluoxetine ( Prozac ) 2060 mg/day ; Paroxetine Paroxetine CR ( Paxil ) 2040 mg/day ; Sertraline ( Zoloft ) 50100 mg/day ; Fluvoxamine ( Luvox ) 100200 mg/day ; Citalopram ( Celexa ) 2040 mg ; Escitalopram ( Lexapro ) 1020 mg/day minimum 12 week . In order meet criterion adequate course CBT OCD , patient receive least 8 session Exposure Response Prevention Therapy ( EX/RP ) license clinician trained CBT OCD . A CBT expert team ensure clinician administer exposure adequate training experience provide treatment . 7 . Participant psychotropic type drug likely interact glutamate least 14 day start study . One exception short act benzodiazepine distress anxiety insomnia ( take 24 hour prior ketamine infusion ) . Participants neuroleptic 1 month fluoxetine 6 week prior study . 8 . For participant young 18 , write informed assent participant consent parent . For participant 19 old , write consent participant permission legal guardian/parent provide information . 1 . Family history psychosis substance abuse/dependence . 2 . History violence 3 . Presence psychotic symptom lifetime diagnosis schizophrenia include auditory visual hallucination presence delusional thinking , bipolar disorder , substanceinduced psychotic disorder , psychosis due general medical condition . 4 . Severely depressed patient Children 's Depression Rating Scale ( CDRS ) ≥ 60 judge clinically risk suicide . 5 . Current diagnosis eat disorder . 6 . Current past history PTSD significant trauma . 7 . Current past diagnosis substance abuse/dependence . 8 . Current past diagnosis pediatric autoimmune neuropsychiatric disorder associate streptococcus ( PANDAS ) . This define follow criterion : abrupt onset OCD symptom ( often comorbid tic ) relapsingremitting symptom course , temporal association symptom exacerbation GroupA betahemolytic streptococcal ( GAS ) infection , association neurological abnormality exacerbation ( adventitious movement , motoric hyperactivity , urinary hesitancy ) , prepubertal age onset . 9 . Participants plan commence cognitivebehavioral therapy period study begin CBT within 8 week prior enrollment . 10 . Documented history hypersensitivity intolerance ketamine . 11 . Female participant either pregnant nursing female participant child bear age sexually active take hormonal birth control . 12 . History significant medical condition might increase risk participation . This would include hypertension ( BP &gt; 140/90 ) , chronic congestive heart failure , tachyarrhythmias , myocardial ischemia , intracranial mass lesion , head injury , globe injury , hydrocephalus . 13 . Concurrent use medication might increase risk participation . This would include : St. John 's Wort , Tramadol atracurium , due potential adverse drugdrug interaction . 14 . Positive urine screen illicit drug 15 . Inability participant parent/guardian read understand English . 16 . Documented history adverse reaction anesthesia .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Obsessive Compulsive Disorder</keyword>
	<keyword>Ketamine</keyword>
	<keyword>Glutamate</keyword>
	<keyword>OCD treatment</keyword>
	<keyword>OCD medication</keyword>
</DOC>